Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
EBIAT
Ratios

Cullinan Therapeutics (CGEM) Shares Issued (2020 - 2023)

Cullinan Therapeutics has reported Shares Issued over the past 4 years, most recently at $38.4 million for Q2 2023.

  • Quarterly results put Shares Issued at $38.4 million for Q2 2023, changed N/A from a year ago — trailing twelve months through Dec 2023 was $38.4 million (up 3229.4% YoY), and the annual figure for FY2024 was $262.7 million, up 584.2%.
  • Shares Issued for Q2 2023 was $38.4 million at Cullinan Therapeutics, up from $1.2 million in the prior quarter.
  • Over the last five years, Shares Issued for CGEM hit a ceiling of $267.3 million in Q1 2021 and a floor of -$267.3 million in Q2 2021.
  • Median Shares Issued over the past 4 years was $1.2 million (2022), compared with a mean of $5.8 million.
  • Biggest five-year swings in Shares Issued: surged 1775.56% in 2021 and later plummeted 299.14% in 2022.
  • Cullinan Therapeutics' Shares Issued stood at $800000.0 in 2020, then surged by 237.75% to $2.7 million in 2021, then tumbled by 57.33% to $1.2 million in 2022, then surged by 3229.4% to $38.4 million in 2023.
  • The last three reported values for Shares Issued were $38.4 million (Q2 2023), $1.2 million (Q4 2022), and -$1.2 million (Q3 2022) per Business Quant data.